SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending upward, primarily fueled by its pivotal announcement of joining the U.S. Department of Energy's Genesis Mission, which is viewed by the community as a significant validation and a de-risking catalyst. This news, alongside broader positive sentiment for AI infrastructure, has reportedly ignited a short squeeze, rewarding patient investors while prompting intense debate among market participants.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending following a substantial contract award from the Space Development Agency, valued at over $800 million, for developing 18 tracking layer satellites. This significant win underscores its role as a key vertically integrated defense-space manufacturer, fueling strong community optimism for future growth and the anticipated Neutron rocket launch.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is generating significant buzz driven by an analyst's bullish initiation and high anticipation for an impending NASA Lunar Terrain Vehicle (LTV) contract award. The community is actively discussing the stock's short squeeze potential, seeing it as a key beneficiary in the expanding space exploration sector. Investors are closely watching for updates on the LTV award, which many believe could be a major catalyst.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as its merger with nuclear fusion company TAE Technologies sparks intense community discussion. Many investors view this strategic pivot into energy as a significant catalyst, with talk of a potential short squeeze and a groundbreaking future, while others express strong skepticism, labeling it a speculative "pump and dump" given the nascent stage of fusion technology and the company's trading history. The market is keenly watching how this ambitious energy play unfolds.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following a significant stock decline, despite exceeding revenue and earnings estimates, as investors reacted negatively to reports of declining sales in Greater China and pressured profit margins. The community is sharply divided, with many viewing the dip as an overreaction and a long-term buying opportunity, while others remain concerned about ongoing challenges in China and rising competition.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing a substantial surge driven by recent analyst upgrades and an enthusiastic response to its expanded hands-free driving capabilities and strategic focus on in-house AI and autonomy. The community is buzzing about a potent short squeeze, repositioning Rivian as a significant tech innovator within the automotive sector, with many anticipating substantial long-term growth.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival (CCL) is trending after recent strong financial results and the significant reinstatement of its quarterly dividend, signaling a notable turnaround for the company. The community is actively discussing its improved profitability and record booking volumes, fueling bullish sentiment for both Carnival and the broader cruise sector. This positive momentum offers reassurance amid prior market concerns, with many anticipating further upside.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing high volatility amid institutional price target adjustments, while community discussions intensely debate its potential for a 'Santa rally' driven by AI and robotaxi advancements versus concerns over current sales and perceived market manipulation. Traders are closely watching the significant options expiration on Quadruple Witching Day, which is contributing to the active directional battles on the stock.

Lamb Weston Holdings, Inc. engages in the production, distribution, and marketing of value-added frozen potato products. It operates through the North America and International segments. The North America segment includes frozen potato products sold in the United States, Canada, and Mexico to quick service and full-service restaurants and chains, foodservice distributors, non-commercial channels, and retailers. International segment primarily includes frozen potato products sold outside of North America. The company was founded in 1950 and is headquartered in Eagle, ID.

Lamb Weston Holdings Inc

Lamb Weston is trending after reporting weaker-than-expected earnings and a lowered outlook, compounded by a leadership transition and restructuring initiatives. Despite a sharp decline in shares, many in the community are actively debating whether the sell-off is overdone, with some "buying the dip" on the belief in resilient demand for frozen potato products. The conversation is further fueled by activist investor engagement hinting at potential strategic changes for the company.

Starfighters Space Inc

Starfighters Space Inc ($FJET) is capturing market attention as a pure-play aerospace company, newly listed and boasting the world's largest commercial supersonic fleet capable of Mach 2 flight and payload launches. The community is actively debating its "moonshot" potential within the burgeoning space sector, with excitement for its unique capabilities countered by concerns over warrant dilution and notable stock volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up - Time to Buy?

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up - Here's Why...

Needham & Company LLC Reaffirms "Hold" Rating for Amicus Therapeutics (NASDAQ:FOLD)

Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research note on Friday...

Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Amicus...

Amicus Therapeutics (NASDAQ:FOLD) Receives Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued a "neutral" rating and issued a $14.50 price target (down from $21.00) on shares of Amicus Therapeutics in a research report on Friday...

<ul class="summary-bullets"><li>The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday.</li><li>Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold.</li><li>BioMarin plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt</li></ul>Amicus Therapeutics (FOLD) shares jumped more than 30% in on Friday, to their highest level since January 2024, after BioMarin Pharmaceutical (BMRN) agreed to acquire the company in a $4.8 billion all-cash deal.The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. The transaction is expected to close in the second quarter of fiscal 2026. Biomarin shares gained 6.6%.Both <a href="https://stocktwits.com/symbol/FOLD">FOLD</a> and <a href="https://stocktwits.com/symbol/BMRN">BMRN</a> were among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Portfolio Expansion And Revenue Pipeline</h2>The acquisition will expand BioMarin’s portfolio, adding two new treatments to its existing medicines for rare inherited metabolic disorders.Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease generated $599 million in combined net revenues over the past four quarters. U.S. exclusivity for Galafold is projected through January 2037 following recent patent settlements.The deal is expected to boost revenue as soon as it closes and add to earnings within the first year. BioMarin expects the acquisition to become meaningfully more accretive from 2027.The company plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt, with Morgan Stanley providing a bridge financing commitment.<h2 class="st-heading-2">IP Dispute Update</h2>Separately, Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold. Under the agreements, the companies will be allowed to launch generics in the U.S. starting January 30, 2037, subject to FDA approval.As part of the settlement, all ongoing Hatch-Waxman litigation between the parties will be terminated, and U.S. antitrust authorities will review the agreements.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for Biomarin on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high' message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:904/100;" src="https://news.stocktwits-cdn.com/BMRN_png_a8236939f5.webp" alt="BMRN.png" width="904" height="100"><figcaption>BMRN's Sentiment Meter And Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>One user highlighted the visibility of BMRN’s FY2027 revenue target.<stembedurl>https://stocktwits.com/DairyQueen505/message/639674012</stembedurl>Retail sentiment for Amicus on the platform remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high message volumes.<figure class="image"><img style="aspect-ratio:922/99;" src="https://news.stocktwits-cdn.com/fold_png_a408903f4b.webp" alt="fold.png" width="922" height="99"><figcaption>FOLD's Sentiment Meter and Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>Year-to-date, FOLD stock has gained 15% while BMRN has declined over 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-new-product-launch-is-lifting-amesite-shares-premarket/cLeiw0iREs7">This New Product Launch Is Lifting Amesite Shares Premarket — Here’s What Investors Are Watching</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal

The acquisition will add two new treatments to BioMarin’s existing medicines for rare inherited metabolic disorders.

Equity

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus...

BioMarin To Acquire Amicus Therapeutics For Around $4.8 Bln

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), a pharmaceutical company, Friday announced that it has entered into a definitive agreement to acquire Amicus Therapeutics (FOLD), a biotech company...

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook BioMarin to Acquire Amicus...

Zacks Industry Outlook Arcutis, Amicus and ANI 

 Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.


5 Biotech Stocks to Watch for Potential Upside

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector. 

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Current Price	$14.20
Prev Close	$10.89
Open	$14.19
Dividend Yield	0.00%
50-Day Moving Average	$9.32
Beta	0.81
Avg. Volume	5.38M
PE Ratio	-243.62

52-Week High	$11.14
52-Week Low	$5.51
Market Capitalization	$3.36B
EPS (Annual)	-$0.1843
Price to Book	14.58
Revenue Per Employee	$1.06M
Enterprise Value/EBITDA	N/A

FOLD
Amicus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FOLD News

FOLDAmicus Therapeutics Inc